Recent Updates
Recently added Catalysts

IMC-P115C

Phase 1

PRAME Positive | Small molecule | Oncology |Immunocore Holdings plc|Last Updated: Feb 25, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment140
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07156136Study of IMC-P115C in Advanced PRAME-Positive CancersPHASE1 RECRUITING 140 — — Nov 7, 2024Aug 30, 2029Feb 25, 202613 Australia, France +2
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of participants with dose-limiting toxicities (DLT)
Up to ~16 months
Percentage of participants with adverse events (AE)
Up to ~16 months
Percentage of participants with serious adverse events (SAE)
Up to ~16 months
Percentage of participants with a dose interruption, reduction, or discontinuation
Up to ~16 months

Percentage of participants with dosing changes or discontinuations.

Secondary Endpoints
Best Overall Response (BOR) as determined by RECIST v1.1 per the Investigator.
Up to ~19 months
Duration of Response (DOR) as determined by RECIST v1.1 per the Investigator.
Up to ~19 months
Progression Free Survival (PFS) as determined by RECIST v1.1 per the Investigator.
Up to ~19 months
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Arm A: IMC-P115C MonotherapyEXPERIMENTALParticipants receive IMC-P115C intravenous (IV) infusion
Interventions
NameTypeDescription
IMC-P115CDRUGIV infusion
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites13

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * HLA-A\*02:01-positive * Meeting PRAME-positive tumor testing requirements * Metastatic or unresectable solid tumors * Have received (or be receiving), relapsed from, be refractory to or intolerant o...

Countries:AustraliaFranceItalySpain
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
MEDIUMMay 26, 2026NCT07156136primaryCompletionDate: changed
LOWMay 24, 2026NCT07156136studyFirstPostDate: changed